key: cord-0699249-svy4cdd9
authors: Sevillano, Gabriela; Ortega-Paredes, David; Loaiza, Karen; Zurita-Salinas, Camilo; Zurita, Jeannete
title: Evidence of SARS-CoV-2 reinfection within the same clade in Ecuador: A case study
date: 2021-04-27
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.04.073
sha: 2e20cf91b2735a760ac726c8bd877e5ca38ee368
doc_id: 699249
cord_uid: svy4cdd9

OBJECTIVES: To date, reported SARS-CoV-2 reinfection cases are mainly based on strains belonging to different clades. As the pandemic advances, a few lineages have become dominant in certain areas which has led to a new type of reinfection by extremely similar strains. Here, we report a reinfection within the same clade in a symptomatic 28-year-old-male in Quito-Ecuador. METHODS: Infection was detected by RT-PCR, immune response was evaluated by antibody testing, patient identity was confirmed by fingerprint. Relatedness was determined through bioinformatics analysis of Illumina WGS samples. RESULTS: Both, the infection and the reinfection strains, were assigned as Nextstrain 20B, Pangolin lineage B.1.1 and GISAID clade O. Our analysis indicated more nucleotide changes than what is expected for reactivation or persistence, 4-6 fold more, based on the natural rate of mutation of SARS-CoV-2 of (≈2-3 nucleotide changes per month), thus supporting a reinfection. Furthermore, after three months of the second infection the patient appears to be susceptible to a new SARS-CoV-2 infection. CONCLUSIONS: Our results showed evidence of SARS-CoV-2 reinfection within the same clade in Ecuador proving that previous exposure to SARS-CoV-2 does not guarantee immunity in all cases.

Reinfection cases of SARS-CoV-2 are being reported worldwide (Arteaga-Livias et al., 2021; Colson et al., 2020; Prado-Vivar et al., 2020; Tillett et al., 2020; VanElslande et al., 2020) . relatively infrequent when compare to the global numbers.

Specially in Latin America, where distinguishing reinfections is understated, as only a small proportion of samples are sequenced (Arteaga-Livias et al., 2021) . In Ecuador, only 0.1% of all its COVID-19 cases are sequenced.

In Ecuador, achieving herd immunity is a challenge as only 0.04% of the population has received the COVID-19 vaccine so far (Google News, 2020; Roser et al., 2020) , despite 97.4% of the population in Ecuador willingness to accept the vaccine (Sarasty et al., 2020) . Therefore, surveillance of reinfections cases in Ecuador is of great importance as reinfections could have implications in vaccine immunity J o u r n a l P r e -p r o o f

Here, we present a case report of an individual who had two distinct COVID-19 illnesses from genetically similar SARS-CoV-2 agents.

RNA was extracted nasopharyngeal swabusing TANBead® Nucleic Acid Extraction Kit (Taiwan Advanced Nanotech Inc., Taiwan). Viral RNA was detected using Allplex™2019 -nCoV Assay (Seegene Inc., Seoul, Korea) IgG and IgM against SARS-CoV-2 nucleoprotein was performed using Enzyme-Linked ImmunoSorbent Assay (ELISA) NovaLisa® SARS-CoV-2 (COVID-19) (Novatec, Dietzenbach, Germany) in the first antibody test. Enzyme-linked fluorescence assay (ELFA) VIDAS® SARS-COV-2 (BioMérieux, Marcy-l'Étoile, Francia) was used in the second one.

To ensure the patient identity in every sample, we used trace genomic DNA in our RNA samples to run a Multiplex STR System for Human Identification, PowerPlex® 21 System (Promega, Madison, Wisconsin, USA).

Whole genome sequencing of SARS-CoV-2 was performed using CleanPlex® SARS-CoV- (Sah et al., 2020) . Cleaned reads were mapped to SARS-CoV-2 reference genome Wuhan-Hu-1 (GenBank accession number NC_045512.2) (Sah et al., 2020; Tillett et al., 2020) , using BWA-MEM 0.7.17 (Sah et al., 2020) . PCR duplicates were marked and removed with Picard 2.23.8 (Tillett et al., 2020) . Variant calling was performed with bcftools 1.11 (-q 25 -Q 35) . Only high-quality variants (QUAL ≥ 20 and DP≥ 5) (Karamitros et al., 2020; Tillett et al., 2020) , were retained and used to generate the consensus sequences. Cross-validation was done with the de novo assembly produced by MEGAHIT 1.2.9 (Sah et al., 2020) , Finally, mutations were identified in the consensus sequences using GISAID's CoVsurver: Mutation Analysis of hCoV-19 (Shu and McCauley, 2017) and Genome Detection (Vilsker et al., 2019) .

290 SARS-CoV-2 consensus genomes from GISAID (Shu and McCauley, 2017) were aligned using MAFFT's rapid calculation of full-length MSA of closely-related viral genomes (Katoh et al., 2002) A NJ phylogenetic tree was draw (Jukes-Cantor substitution model) and visualized using Phylo.io (Robinson et al., 2016) . Clades were assigned using GISAID (Shu and McCauley, 2017) , Nextstrain (Tillett et al., 2020) , and Pangolin (Rambaut et al., 2020) .

This work was approved under a consent waiver by the Expedited Committee of the General Coordination for Strategic Development in Health as stipulated by the Ecuadorian Ministry of Public Health Resolution N° 074-2020.

The patient was a 28-year-old male residing in Quito-Ecuador. . During the first infection, he had symptoms consistent with viral infection (sore throat, cough, headache, nausea, and diarrhea, anxiety and panic attacks), which had started on July 15th, 2020. The diagnosis was confirmed by a positive SARS-CoV-2 RT-PCR test (CT=29.9) from a nasopharyngeal swab on July 20th, 2020. . On July 25th, 2020, he tested negative for IgG and IgM against SARS-CoV-2. He came out of isolation on August 4th, 2020 after two negative SARS-CoV-2 RT-PCR tests from nasopharyngeal swabs taken 24h apart. On August 10th, 2020, he tested negative for IgG and IgM against SARS-CoV-2.

About 3 months later, October 26th, the patient presented anosmia, ageusia, fever, headache.

. 

Previously, a reinfection case with different clades was reported in Ecuador (Prado-Vivar et al., 2020) , and a reinfection case with the same clade was reported in USA (Tillett et al., J o u r n a l P r e -p r o o f 2020). However, unlike the previous case in Ecuador (Prado-Vivar et al., 2020) , and USA study (Tillett et al., 2020) , we were able to assess the immune response of the first infection of SARS-CoV-2.

According to the PAHO definitions (Pan American Health Organization, 2020), and ECDC guidelines (European Centre for Disease Prevention and Control, 2020), a suspected reinfection happens if the elapsed time between one of confirmatory negative tests and a subsequent positive PCR test, range from >=45 ->=90 days. , a confirmed case has an interval without symptoms or a negative laboratory test (epidemiological criteria) and the secondary infection belongs to a different clade or lineages (laboratory criteria), regardless of the number of SNVs. If the infectious virus identification through the quantification of viral load through the cycle threshold (CT) of a PCR is < 37 in both cases. A cycle threshold (CT) of < 37 is defined as a positive test while a CT > 40 is defined as a negative test (Xing et al., 2020) . Finally, if the mutation rate within the host makes it possible to rule out persistence and double infections by means of a sequence/phylogenetic analysis. Our case had an interval of 82 days since the first infection, had an interval without symptoms and with two negative laboratory test, thus ruling out the phenomenon known as re-positivity;

where asymptomatic patients carry a small quantity of the virus (Lan et al., 2020; Xing et al., 2020) . This factor, have been in cases reported where a PCRis followed by a PCR + after 5-13 days. Therefore, a true reinfection is more likely than a re-activation or re-positivit y.

The patient had symptoms of COVID in both cases, so we discarded false positivity. Both our infections were CT< 37. The first infection CT=29.9, the second infection CT=17.8. The secondary infection came from the same clade. However, our analysis showed more nucleotide changes than expected for persistence, approximately 4-6 fold more (based on the J o u r n a l P r e -p r o o f natural rate of mutation of SARS-CoV-2 of ≈2-3 nucleotide changes per month) (Callaway, 2020; Candido et al., 2020) , indicating a reinfection wheregenetic discordance between the specimens was greater than what it can be accounted for in vivo evolution (Tillett et al., 2020) .

The patient presented different COVID symptoms. Being the first episode more aggressive than the second one. Similar results were reported in reinfection cases in Belgium, and Hong

Kong VanElslande et al., 2020) .

The first infection COVID-19 antibodies were not detected, while in the second infection COVID-19 antibodies were detected. Similar to the event reported in the Hong Kong patient . We can speculate that the first infection was caused by a virus that caused a worst disease due to its ability to evade the immune system in the patient due to the Spike mutations (Weisblum et al., 2020) . . Interestingly, after about three months later from the second infection COVID antibodies are not detectable again in the patient, suggesting the possibility of a third infection. However, a profound analysis of the patient's immune system is yet due to verify this.

Several mutations in the spike protein receptor binding domain and N-terminal domain have been shown to confer reduced susceptibility to neutralizing antibodies (Weisblum et al., 2020) . For our patient, there were two amino acid residues that differed in the spike protein between the first and second infection: L229F and V635I. L229F was first found in North

COVID-19 reinfection? A suspected case in a Peruvian patient

The coronavirus is mutating -does it matter?

Evolution and epidemic spread of SARS-CoV-2 in Brazil

Evidence of SARS-CoV-2 re-infection with a different genotype

Severe acute respiratory syndrome coronavirus 2: virus mutations in specific European populations

European Centre for Disease Prevention and Control. Threat Assessment Brief: Reinfection with SARS-CoV-2: considerations for public health

Lipniacki 1 T. SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations

Human SARS CoV-2 spike protein mutations

SARS-CoV-2 exhibits intra-host genomic plasticity and low-frequency polymorphic quasispecies

MAFFT: A novel method for rapid multiple sequence alignment based on fast Fourier transform

Positive RT-PCR Test Results in Patients Recovered from COVID-19

SNPs or RNA modifications? Concerns on mutation-based evolutionary studies of SARSCoV-2

Pan American Health Organization. Interim guidelines for detecting cases of reinfection by SARS-CoV-2-PAHO/WHO 2020

A case of SARS-CoV-2 reinfection in Ecuador

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

io: Interactive Viewing and Comparison of Large Phylogenetic Trees on the Web

Coronavirus Pandemic (COVID-19) -Statistics and Research -Our World in Data

Complete Genome Sequence of a 2019 Novel Coronavirus (SARS-CoV-2) Strain Isolated in Nepal

The demand for a COVID-19 vaccine in Ecuador

Global initiative on sharing all influenza data -from vision to reality

Genomic evidence for reinfection with SARS-CoV-2: a case study

COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing

Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain

Genome Detective: An automated system for virus identification from high-throughput sequencing data

Escape from neutralizing antibodies 1 by SARS-CoV-2 spike protein variants

Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China